Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports
Executive Summary
Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available
You may also be interested in...
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Abilify “Dear Doctor” letter
Bristol-Myers Squibb's March 25 "Dear Doctor" 1letter on the atypical antipsychotic class warning for diabetes says "an exhaustive review of the Abilify database revealed no increased signal for diabetes," although "additional information is needed to confirm this." Bristol and Otsuka updated Abilify (aripiprazole) labeling in March to reflect FDA's requested class warning (2"The Pink Sheet" April 5, 2004, p. 32)...